MedTrace Logo

Omega-3 Plus Low-Dose Aspirin in Smokers With Stage III Periodontitis

NCT07673185 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-07-08

No results posted yet for this study

Summary

This randomized double-blind placebo-controlled clinical trial aims to evaluate the clinical and biochemical effects of omega-3 fatty acids combined with low-dose aspirin as an adjunct to scaling and root planing (SRP) in smoker patients with Stage III periodontitis. The study compares test and control groups regarding periodontal clinical parameters and gingival crevicular fluid interleukin-1 beta (IL-1β) levels Or other inflammatory markers that will be determined later at baseline, 3 months, and 6 months following treatment

Conditions

Interventions

DRUG

Omega-3 Fatty Acids (EPA plus DHA) plus low dose aspirin

participants receive omega3 fatty acid (EPA640+DHA480) plus low dose aspirin (75mg) orally once for 6 months following scaling and root planning

DRUG

Placebo

matching placebo capsules administered orally once daily for 6 months following scaling and root planning

Sponsors & Collaborators

  • Al-Azhar University

    lead OTHER

Principal Investigators

  • naglaa M EL wakeel, professor · Faculty of Dental Medicine for Girls, Al-Azhar University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-15
Primary Completion
2026-07-30
Completion
2026-10-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07673185 on ClinicalTrials.gov